Agreement to Sell Coris Bioconcept SRL
Avacta agrees to sell Coris Bioconcept for £2.15m upfront plus £0.615m earn-out, completing transition to pure-play therapeutics.
- Upfront cash consideration £2.15 Million
- Earn-out based on future performance up to £0.615 Million
- Coris FY24 revenue €5.22 Million
- Coris FY24 EBITDA €0.215 Million negative
- Coris net assets at year-end 2024 €4.14 Million
- Non-cash impairment charge £6.8 Million
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
LONDON AND PHILADELPHIA - July 28, 2025 - Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing innovative, targeted oncology drugs, today announced the sale of Coris Bioconcept SRL ("Coris") to 3B BlackBio Dx Ltd for an upfront cash consideration of £2.15 Million (including net cash & customary working capital adjustments) with an additional earn-out based on future business performance of up to £0.615 Million. Completion of the sale is expected in August 2025, subject to customary closing conditions.
| This sale follows the divestment of Launch Diagnostics completed in March 2025 and is the important final step in the Company's goal of becoming a pure-play therapeutics business. The sale proceeds will be used to further Avacta's pre | CISION® platform. |
Coris reported unaudited revenue of €5.22 Million for the financial year ended 31 December 2024 ("FY24"), primarily driven by sales from non-COVID products. In FY24 Coris recorded negative EBITDA of €0.215 Million and its net assets at the year-end stood at €4.14 Million.
Following the sale of Coris, the Company's cash runway will extend further into Q1 2026.
In the year ending 31 December 2024, the Group reported a noncash impairment charge of £6.8 Million as a result of this disposal.
| Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said: "This disposal marks the pivotal final step in Avacta's transition to a pure-play therapeutics company. We are now fully focused on advancing our promising peptide drug conjugate pipeline powered by our innovative pre | CISION® technology, which is delivering precision oncology treatments that have the potential to make a meaningful impact on patient outcomes." | |||
| About the pre | CISION® Platform | |||
| The pre | CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre | CISION® platform harnesses this tumor specific protease to cleave pre | CISION® peptide drug conjugates and pre | CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients. |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.